Webcast Presentation Scheduled for Monday, October 6, 2008 at 3:00 p.m. EDT
BROOMFIELD, Colo., Oct. 2 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that Richard Brewer, the company's president and chief executive officer, and Dr. Michael Bristow, M.D., ARCA's chairman and chief science and medical officer, will present at the Third Annual JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 3:00 p.m. EDT in New York City.
ARCA biopharma and Nuvelo, Inc. (Nasdaq: NUVO) announced on September 25, 2008 that they have entered into a definitive merger agreement, expected to create a cardiovascular-focused, late-stage biotechnology company. The presentation will discuss the assets of both companies, including ARCA's lead product Gencaro(TM) (bucindolol hydrochloride) a near-term commercial opportunity, as well as Nuvelo's mid-stage pipeline asset, novel short-acting anticoagulant NU172, to drive long-term growth. ARCA recently announced that the FDA has accepted a New Drug Application for Gencaro. The presentation will also discuss the structure and strategic plan of the combined company, pending the closing of the merger.
A live audio webcast of the presentation will be available online via the ARCA biopharma website at http://www.arcabiopharma.com, the Investor Relations portion of Nuvelo's website at http://www.nuvelo.com or http://www.wsw.com/webcast/jmp7/nuvo/.
About ARCA biopharma
|SOURCE ARCA biopharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved